Skip to main content

Table 3 Factors associated with treatment delay among bacteriologically confirmed TB patients who received treatment in 21 township health centres of the Mandalay Region of Myanmar between January and June 2017

From: Pre-treatment loss to follow-up and treatment delay among bacteriologically-confirmed tuberculosis patients diagnosed in Mandalay Region, Myanmar

Variables

Total (n)

Treatment delay (n (%))

RR (95%CI)

aRR (95% CI)

Total

940

46 (4.9)

  

Age (years)

 < 15

3

0 (0.0)

  

 15–44

536

18 (3.4)

Ref

Ref

 45–64

308

21 (6.8)

2.0 (1.1–3.8)

1.9 (1.0–3.6)

 ≥ 65

93

7 (7.5)

2.2 (0.9–5.2)

2.0 (0.8–4.9)

Gender

 Male

701

36 (5.1)

Ref

Ref

 Female

239

10 (4.2)

0.8 (0.4–1.6)

0.8 (0.4–1.8)

Phone number

    

 Recorded

31

2 (6.5)

0.3 (0.0–2.2)

 

 Not recorded

909

44 (4.8)

Ref

 

HIV status

 Positive

46

4 (8.7)

2.03 (0.7–5.5)

1.86 (0.6–5.4)

 Negative

864

37 (4.3)

Ref

Ref

 Unknown

30

5 (16.7)

3.89 (1.6–9.2)

3.76 (1.4–9.9)

History of TB treatment

 Yes

67

6 (8.9)

2.08 (0.9–4.9)

1.89 (0.7–4.8)

 No

630

27 (4.3)

Ref

Ref

 Unknown

243

13(5.4)

1.24 (0.6–2.4)

1.15 (0.6–2.3)

Sputum result

 Smear positive

913

43 (4.7)

Ref

Ref

 Smear negative Xpert positive

27

3 (11.1)

2.35 (0.8–7.1)

1.46 (0.4–5.1)

 Not recorded

135

12(8.9)

0.73 (0.4–1.4)

 

Site of sputum microscopy

 Low volume

264

10 (3.8)

Ref

Ref

 Moderate volume

261

13 (4.9)

1.3 (0.6–2.9)

1.5 (0.6–3.4)

 High volume

415

23 (5.5)

1.5 (0.7–3.0)

1.6 (0.7–3.4)

  1. TB tuberculosis, RR relative risk, aRR adjusted relative risk (adjusted for age, gender, HIV status, history of TB treatment, sputum result, site of sputum microscopy), Ref reference group. Text in boldface indicates the statistical significance at p value < 0.001